Literature DB >> 11994560

Possible mechanisms of aspirin resistance.

Josie A Cambria-Kiely1, Pritesh J Gandhi.   

Abstract

Data regarding possible mechanisms of aspirin (ASA) resistance in patients with recurrent myocardial infarction (MI) or vascular ischemia are limited. Five major possible mechanisms of ASA resistance are documented in the primary literature and are discussed in this paper. These mechanisms include: (1) inadequate blockade of erythrocyte-induced platelet activation; (2) biosynthesis of F2-isoprostane 8-iso-prostaglandin (PGF2alpha), a bioactive product of arachidonic acid peroxidation; (3) stimulation of platelet aggregation by cigarette smoking; (4) ASA resistant platelet aggregability by increased levels of norepinephrine, as seen during excessive exercise or periods of mental stress; and (5) increased platelet sensitivity to collagen. Recognizing mechanisms of platelet activation and identifying reversible risk factors such as smoking and mental stress may help decrease the occurrence of ASA resistance and possibly improve patient outcomes. Until more definitive data become available, when prescribing and dosing ASA for the prevention of MI or vascular ischemia, clinicians should identify possible risk factors for ASA resistance. Whether or not patients at risk for ASA resistance are candidates for additive antiplatelet therapy remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994560     DOI: 10.1023/a:1015324310374

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  29 in total

Review 1.  Aspirin.

Authors:  E H Awtry; J Loscalzo
Journal:  Circulation       Date:  2000-03-14       Impact factor: 29.690

2.  Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage.

Authors:  J D Morrow; B Frei; A W Longmire; J M Gaziano; S M Lynch; Y Shyr; W E Strauss; J A Oates; L J Roberts
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

3.  Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin.

Authors:  M Hurlen; I Seljeflot; H Arnesen
Journal:  Thromb Res       Date:  2000-09-01       Impact factor: 3.944

4.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

5.  Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.

Authors:  S R Steinhubl; J D Talley; G A Braden; J E Tcheng; P J Casterella; D J Moliterno; F I Navetta; P B Berger; J J Popma; G Dangas; R Gallo; D C Sane; J F Saucedo; G Jia; A M Lincoff; P Theroux; D R Holmes; P S Teirstein; D J Kereiakes
Journal:  Circulation       Date:  2001-05-29       Impact factor: 29.690

6.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

Authors:  P Patrignani; P Filabozzi; C Patrono
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

7.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

8.  The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study.

Authors:  P M Ridker; J E Manson; J E Buring; S Z Goldhaber; C H Hennekens
Journal:  Am Heart J       Date:  1991-12       Impact factor: 4.749

9.  Cigarette smoking--induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease.

Authors:  J W Davis; C R Hartman; H D Lewis; L Shelton; D A Eigenberg; K M Hassanein; C E Hignite; H A Ruttinger
Journal:  J Lab Clin Med       Date:  1985-04

10.  Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden.

Authors:  L C Wallentin
Journal:  J Am Coll Cardiol       Date:  1991-12       Impact factor: 24.094

View more
  10 in total

1.  Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin.

Authors:  Cezary Watala; Justyna Pluta; Jacek Golanski; Marcin Rozalski; Malgorzata Czyz; Zygmunt Trojanowski; Józef Drzewoski
Journal:  J Mol Med (Berl)       Date:  2004-11-10       Impact factor: 4.599

Review 2.  Aspirin resistance, an emerging, often overlooked, factor in the management of patients with coronary artery disease.

Authors:  Amgad N Makaryus
Journal:  Clin Cardiol       Date:  2006-04       Impact factor: 2.882

Review 3.  Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4.

Authors:  Wei C Lau; Paul A Gurbel
Journal:  Pharm Res       Date:  2006-10-24       Impact factor: 4.200

4.  Follow-up of aspirin-resistant patients with end-stage kidney disease.

Authors:  Kadriye Orta Kilickesmez; Cuneyt Kocas; Okay Abaci; Baris Okcun; Bilal Gorcin; Tevfik Gurmen
Journal:  Int Urol Nephrol       Date:  2012-06-20       Impact factor: 2.370

5.  Association of the platelet membrane glycoprotein I a C807T gene polymorphism with aspirin resistance.

Authors:  Guanhua Su; Zhaohui Wang; Yanping Ding
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-12

Review 6.  Aspirin resistance: an update.

Authors:  Gilead I Lancaster; Janardhan Srinivasan; Hitender Jain
Journal:  Curr Atheroscler Rep       Date:  2009-03       Impact factor: 5.113

Review 7.  Aspirin resistance and genetic polymorphisms.

Authors:  Josie A Cambria-Kiely; Pritesh J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2002-08       Impact factor: 2.300

Review 8.  The Clinical Efficacy of Ginkgo biloba Leaf Preparation on Ischemic Stroke: A Systematic Review and Meta-Analysis.

Authors:  Shuang Zhao; Hong Zheng; Yawei Du; Runlei Zhang; Peilin Chen; Rong Ren; Shengxian Wu
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-09       Impact factor: 2.629

9.  The role of genetics in pre-eclampsia and potential pharmacogenomic interventions.

Authors:  Paula Juliet Williams; Linda Morgan
Journal:  Pharmgenomics Pers Med       Date:  2012-01-20

10.  The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?

Authors:  Raul Altman; Héctor L Luciardi; Juan Muntaner; Ramón N Herrera
Journal:  Thromb J       Date:  2004-01-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.